INSP Valuation

Inspire Medical Systems Inc

Add to Watchlist

Advanced Chart

88.340

+0.57(0.649%)1D

Overview
Forecast
Valuation
Earnings

INSP Relative Valuation

INSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INSP is overvalued; if below, it's undervalued.

Historical Valuation

Inspire Medical Systems Inc (INSP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.70 is considered Undervalued compared with the five-year average of -3.63. The fair price of Inspire Medical Systems Inc (INSP) is between 172.61 to 586.18 according to relative valuation methord. Compared to the current price of 88.34 USD , Inspire Medical Systems Inc is Undervalued By 48.82%.

Relative Value

Fair Zone

172.61-586.18

Current Price：88.34

48.82%

Undervalued

92.50

Trailing

Forward

13.57

EV/EBITDA

Inspire Medical Systems Inc. (INSP) has a current EV/EBITDA of 13.57. The 5-year average EV/EBITDA is -36.12. The thresholds are as follows: Strongly Undervalued below -380.72, Undervalued between -380.72 and -208.42, Fairly Valued between 136.19 and -208.42, Overvalued between 136.19 and 308.49, and Strongly Overvalued above 308.49. The current Forward EV/EBITDA of 13.57 falls within the Historic Trend Line -Fairly Valued range.

201.18

EV/EBIT

Inspire Medical Systems Inc. (INSP) has a current EV/EBIT of 201.18. The 5-year average EV/EBIT is 3.37. The thresholds are as follows: Strongly Undervalued below -594.59, Undervalued between -594.59 and -295.61, Fairly Valued between 302.35 and -295.61, Overvalued between 302.35 and 601.33, and Strongly Overvalued above 601.33. The current Forward EV/EBIT of 201.18 falls within the Historic Trend Line -Fairly Valued range.

2.70

Inspire Medical Systems Inc. (INSP) has a current PS of 2.70. The 5-year average PS is 13.77. The thresholds are as follows: Strongly Undervalued below -2.05, Undervalued between -2.05 and 5.86, Fairly Valued between 21.68 and 5.86, Overvalued between 21.68 and 29.59, and Strongly Overvalued above 29.59. The current Forward PS of 2.70 falls within the Undervalued range.

14.58

P/OCF

Inspire Medical Systems Inc. (INSP) has a current P/OCF of 14.58. The 5-year average P/OCF is -85.97. The thresholds are as follows: Strongly Undervalued below -537.37, Undervalued between -537.37 and -311.67, Fairly Valued between 139.73 and -311.67, Overvalued between 139.73 and 365.43, and Strongly Overvalued above 365.43. The current Forward P/OCF of 14.58 falls within the Historic Trend Line -Fairly Valued range.

17.67

P/FCF

Inspire Medical Systems Inc. (INSP) has a current P/FCF of 17.67. The 5-year average P/FCF is -28.41. The thresholds are as follows: Strongly Undervalued below -478.79, Undervalued between -478.79 and -253.60, Fairly Valued between 196.78 and -253.60, Overvalued between 196.78 and 421.96, and Strongly Overvalued above 421.96. The current Forward P/FCF of 17.67 falls within the Historic Trend Line -Fairly Valued range.

Inspire Medical Systems Inc (INSP) has a current Price-to-Book (P/B) ratio of 3.83. Compared to its 3-year average P/B ratio of 11.02 , the current P/B ratio is approximately -65.27% higher. Relative to its 5-year average P/B ratio of 16.50, the current P/B ratio is about -76.79% higher. Inspire Medical Systems Inc (INSP) has a Forward Free Cash Flow (FCF) yield of approximately 3.27%. Compared to its 3-year average FCF yield of 0.40%, the current FCF yield is approximately 713.43% lower. Relative to its 5-year average FCF yield of -0.08% , the current FCF yield is about -4217.93% lower.

3.83

P/B

Median3y

11.02

Median5y

16.50

3.27

FCF Yield

Median3y

0.40

Median5y

-0.08

Competitors Valuation Multiple

The average P/S ratio for INSP's competitors is 2.58, providing a benchmark for relative valuation. Inspire Medical Systems Inc Corp (INSP) exhibits a P/S ratio of 2.70, which is 5.03% above the industry average. Given its robust revenue growth of 10.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

INSP.N

Inspire Medical Systems Inc

Alphatec Holdings Inc

Procept Biorobotics Corp

Loss

48.41%

2.26B

Performance Decomposition

Market capitalization of INSP decreased by 50.87% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 29.41 to 50.38.

The secondary factor is the Revenue Growth, contributed 10.82%to the performance.

Overall, the performance of INSP in the past 1 year is driven by P/E Change. Which is more unsustainable.

10.82%

195.89M → 217.09M

Revenue Growth

-133.00%

5.00 → -1.65

Margin Expansion

71.31%

29.41 → 50.38

P/E Change

-50.87%